[1]郑燕林,彭晓丽,陈廷,等.Lucentis治疗黄斑脉络膜新生血管1年的临床疗效观察[J].眼科新进展,2016,36(4):348-351.[doi:10.13389/j.cnki.rao.2016.0094]
　ZHENG Yan-Lin,PENG Xiao-Li,CHEN Ting,et al.Clinical effects of Lucentis in treatment of macular choroid neovascularization for l year[J].Recent Advances in Ophthalmology,2016,36(4):348-351.[doi:10.13389/j.cnki.rao.2016.0094]
点击复制

Lucentis治疗黄斑脉络膜新生血管1年的临床疗效观察
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
36卷
期数:
2016年4期
页码:
348-351
栏目:
应用研究
出版日期:
2016-04-05

文章信息/Info

Title:
Clinical effects of Lucentis in treatment of macular choroid neovascularization for l year
作者:
郑燕林; 彭晓丽; 陈廷; 郑淼; 智亚伟; 耿艳
610072　四川省成都市，成都中医药大学附属医院眼科（郑燕林）；044000　山西省运城市，运城市眼科医院（彭晓丽）；610072　四川省成都市，成都中医药大学（陈廷，郑淼，智亚伟，耿艳）
Author(s):
ZHENG Yan-Lin ;  PENG Xiao-Li ;  CHEN Ting ; ZHENG Miao ; ZHI Ya-Wei ;  GENG Yan
Department of Ophthalmology , the Teaching Hospital of Chengdu Traditional Chinese Medicine ( ZHENG Yan-Lin) . Chengdu 610072 , Sichuan Province , China ; Yuncheng Eye Hospital ( PENG Xiao-Li ) , Yuncheng 044000 , Shanxi Province . China ; Chengdu Traditional Chinese Medicine( CHEN Ting, ZHENG Miao , ZHI Ya-Wei, GENG Yan ) , Chengdu 610072 , Sichuan Province , China
关键词:
雷珠单抗; 年龄相关性黄斑变性; 高度近视黄斑病变
Keywords:
ranibizumab ;  age-related macular degeneration;  high myopia macular degeneration
DOI:
10.13389/j.cnki.rao.2016.0094
文献标志码:
A
摘要:
目的　采用１＋ＰＲＮ的方案治疗年龄相关性黄斑变性（ａｇｅ-ｒｅｌａｔｅｄｍａｃｕｌａｒｄｅｇｅｎ-ｅｒａｔｉｏｎ，ＡＭＤ）及高度近视黄斑脉络膜新生血管（ｃｈｏｒｏｉｄａｌｎｅｏｖａｓｃｕｌａｒｉｚａｔｉｏｎ，ＣＮＶ），观察其１ａ疗效。方法　收集２０１２年７月至２０１４年４月在我院眼科就诊，确诊为黄斑区ＣＮＶ（继发于ＡＭＤ或高度近视者）并接受单一的玻璃体内注射Ｌｕｃｅｎｔｉｓ（单次剂量０．５ｍｇ／０．０５ｍＬ）的７３例（７９眼；其中ＡＭＤ患者３８眼，高度近视黄斑ＣＮＶ患者４１眼）患者的临床资料。记录治疗后１ｄ、１周及１ａ内每月的最佳矫正视力（ｂｅｓｔｃｏｒｒｅｃｔｅｄｖｉｓｕａｌａ-ｃｕｉｔｙ，ＢＣＶＡ）、黄斑中心视网膜厚度（ｃｅｎｔｒａｌｒｅｔｉｎａｔｈｉｃｋｎｅｓｓ，ＣＲＴ）以及１ａ后地图状萎缩进展情况。结果　治疗后不同时间点ＡＭＤ与高度近视患者的平均ＢＣＶＡ均较治疗前提高，差异均有统计学意义（均为Ｐ＜０．０５），其中治疗后１周～３个月提高幅度最明显，治疗后３个月～１ａ基本保持平稳。ＣＲＴ变化情况与ＢＣＶＡ一致。１ａ观察终点时，所有患者中治疗眼与非治疗眼地图状萎缩的发展并无明显差异。随访期内，１０眼结膜下出血，１眼虹膜色素脱失，１眼轻度视网膜劈裂，未发现眼压升高、视网膜脱离、眼内炎等其他局部并发症及全身不良反应。结论　采用１＋ＰＲＮ治疗方案治疗ＡＭＤ与高度近视黄斑ＣＮＶ在１ａ期间是安全有效的，注射次数较少的情况下对患者地图状萎缩进展影响不大。
Abstract:
Objective To observe the clinical effects of intravitreal injection of ranibizumab in treatment of macular choroid neovascularization ( CNV) secondary to age-related macular degeneration (AMD) and high myopia ( HM) for I year using an on-demand regimen( I + PRN) . Methods Seventy-nine eyes of 73 patients ( 38 eyes of AMD patients and 41 eyes of HM macular CNV patients) with CNV were collected from July 2012 to April 2014 in our hospital. All affected eye were treated only with intravitreal injection of rarubizumab ( single dose 0. 5 m~0. 05 mL) . Follow-up time was I day, I week and monthly for I year. Best corrected visual acuity ( BCVA) .macular retinal thickness (CRT) were assessed at each follow-up time. Auto-fluorescence ( AF) was used before the first injection and I year after the first injection to assesse the progress of the geographic atrophy ( GA) . Results BCVA of all eyes were obviously increased at postoperative different time . there were statistical differences compared with pre-operation ( all P < 0. 05 ) ,in which BCVA was increased more obviously from I week t0 3 months , and remained stable from 3 months to I year. CRT change was consistent with BCVA. There was no significant difference about GA after I year between the affected eye and non-affected eye. In the follow-up time. the intraocular pressure did not increase in all patients, but there were 10 eyes with subconjunctival hemorrhage, I eye with ris depigmentation , I eye with slightly retinoschisis . and no retinal detachment . endophthalmitis and other topical adverse events was observed. No serious systemic was observed. Conclusion Using I + PRN therapy in the treatment of CNV secondary to AMD and HM macular CNV is safe and effective during the period of I year , and the few injections have little effects on the progress of GA.

相似文献/References:

[1]范姜砾 王雨生 张鹏.湿性年龄相关性黄斑变性患者血浆中相关抗氧化酶水平测定[J].眼科新进展,2012,32(5):000.
[2]王毅 李罗翔 李娟 曾庆华.ApoE基因缺失小鼠视网膜及Bruch膜组织形态观察[J].眼科新进展,2013,33(1):000.
[3]徐新荣 仲路 黄冰林 魏源华 周欣 王玲 王富强.年龄相关性黄斑变性血浆蛋白质组学初步研究[J].眼科新进展,2013,33(2):000.
[4]党亚龙 陈彬川 穆雅林 赵满丽 朱豫.i-MP对产生2型脉络膜新生血管的年龄相关性黄斑变性患者视力及黄斑厚度的影响[J].眼科新进展,2013,33(2):000.
[5]王毅 李罗翔 李进辉 李娟 曾庆华.血脂异常ApoE基因缺失小鼠视网膜色素上皮细胞胞浆内黑色素和脂褐素的改变[J].眼科新进展,2013,33(7):000.
[6]罗文婷 孙大卫.血管黏附蛋白-1在眼科疾病中的研究进展[J].眼科新进展,2013,33(8):000.
[7]陆秉文 吴星伟.光动力疗法治疗年龄相关性黄斑变性的研究进展[J].眼科新进展,2013,33(4):000.
[8]栾兰 姚勇.湿性年龄相关性黄斑变性的治疗进展[J].眼科新进展,2013,33(4):000.
[9]李姣 王兴荣 崔彦 刘正峰 王影 李洋.雷珠单抗选择性体外抑制睫状体恶性黑色素瘤[J].眼科新进展,2013,33(11):000.
[10]胡艳红 祁明信 郭娜 陈胜 柯发杰.渗出型年龄相关性黄斑变性患者外周血CCR3的表达[J].眼科新进展,2013,33(11):000.
[11]胡军平,杨华,李国栋,等.光动力疗法联合玻璃体内注射雷珠单抗治疗湿性年龄相关性黄斑变性后黄斑区中心视野的改变[J].眼科新进展,2015,35(11):1039.[doi:10.13389/j.cnki.rao.2015.0284]
　HU Jun-Ping,YANG Hua,LI Guo-Dong,et al.Macular visual field changes after combined photodynamic therapy and intravitreal injection of ranibizumab for neovacular age-related macular degeneration[J].Recent Advances in Ophthalmology,2015,35(4):1039.[doi:10.13389/j.cnki.rao.2015.0284]
[12]赵露,洪慧,谢国丽,等.玻璃体内注射雷珠单抗对湿性年龄相关性黄斑变性患者脉络膜厚度及睫状后动脉血流的影响[J].眼科新进展,2016,36(8):745.[doi:10.13389/j.cnki.rao.2016.0198]
　ZHANG Lu,HONG Hui,XIE Guo-Li,et al.Effects of intravitreal ranibizumab injection on subfoveal choroidal thickness and posterior ciliary artery hemodynamics in patients with wet age-related macular degeneration[J].Recent Advances in Ophthalmology,2016,36(4):745.[doi:10.13389/j.cnki.rao.2016.0198]
[13]刘志南,管怀进.雷珠单抗和阿柏西普对年龄相关性黄斑变性患者外层视网膜管状结构的影响[J].眼科新进展,2019,39(10):952.[doi:10.13389/j.cnki.rao.2019.0217]
　LIU Zhi-Nan,GUAN Huai-Jin.Effects of ranibizumab and aflibercept on outer retinal tubulation of patients with age-related macular degeneration[J].Recent Advances in Ophthalmology,2019,39(4):952.[doi:10.13389/j.cnki.rao.2019.0217]
[14]张雨晴,邵毅,葛倩敏,等.玻璃体内注射雷珠单抗对年龄相关性黄斑变性患者眼表的影响[J].眼科新进展,2020,40(3):235.[doi:10.13389/j.cnki.rao.2020.0055]
　ZHANG Yuqing,SHAO Yi,GE Qianmin,et al.Clinical study of ocular surface damage caused by intravitreal injection of Ranibizumab in patients with age-related macular degeneration[J].Recent Advances in Ophthalmology,2020,40(4):235.[doi:10.13389/j.cnki.rao.2020.0055]
[15]胡伟男,蔡文婷,邹爱琪,等.精氨酸-甘氨酸-天冬氨酸修饰的星型高分子负载雷珠单抗对脉络膜新生血管靶向治疗作用[J].眼科新进展,2021,41(2):130.[doi:10.13389/j.cnki.rao.2021.0027]
　HU Weinan,CAI Wenting,ZOU Aiqi,et al.Targeted therapy effect of arginine-glycine-aspartate modified star polymer loaded ranibizumab on choroidal neovascularization[J].Recent Advances in Ophthalmology,2021,41(4):130.[doi:10.13389/j.cnki.rao.2021.0027]
[16]臧涵怡,包欣,赵伟.雷珠单抗1+PRN和3+PRN治疗湿性年龄相关性黄斑变性的对比研究[J].眼科新进展,2021,41(11):1072.[doi:10.13389/j.cnki.rao.2021.0225]
　ZANG Hanyi,BAO Xin,ZHAO Wei.Efficacy of ranibizumab 1+PRN and 3+PRN in the treatment of wet age-related macular degeneration[J].Recent Advances in Ophthalmology,2021,41(4):1072.[doi:10.13389/j.cnki.rao.2021.0225]
[17]赵文,赵斐,李敏,等.CFH基因多态性与玻璃体液VEGF对年龄相关性黄斑变性患者抗VEGF疗效影响的交互作用[J].眼科新进展,2022,42(12):962.[doi:10.13389/j.cnki.rao.2022.0197]
　ZHAO Wen,ZHAO Fei,LI Min,et al.Interaction between complement factor H gene polymorphism and vascular endothelial growth factor in vitreous humor on anti-vascular endothelial growth factor efficacy in patients with age-related macular degeneration[J].Recent Advances in Ophthalmology,2022,42(4):962.[doi:10.13389/j.cnki.rao.2022.0197]

更新日期/Last Update: 2016-04-01